STAB (Statera BioPharma) YoY EPS Growth: 85.11% (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma YoY EPS Growth?

Statera BioPharma STAB YoY EPS Growth is 85.11% as of Sep. 2022.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Statera BioPharma's YoY EPS Growth for the quarter that ended in Sep. 2022 was 85.11%.

Statera BioPharma's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.07.

Statera BioPharma YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma YoY EPS Growth Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
YoY EPS Growth
0.00 -273.81 -515.71

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -112.67 -1,219.39 2.91 72.87 85.11

Statera BioPharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Statera BioPharma's YoY EPS Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EPS Growth (A: Dec. 2021 )
=(Earnings per Share (Diluted) (A: Dec. 2021 )-Earnings per Share (Diluted) (A: Dec. 2020 ))/ | Earnings per Share (Diluted) (A: Dec. 2020 ) |
=(-2.9--0.471)/ | -0.471 |
=-515.71 %

Statera BioPharma's YoY EPS Growth for the quarter that ended in Sep. 2022 is calculated as:

YoY EPS Growth (Q: Sep. 2022 )
=(Earnings per Share (Diluted) (Q: Sep. 2022 )-Earnings per Share (Diluted) (Q: Sep. 2021 )) / | Earnings per Share (Diluted) (Q: Sep. 2021 )) |
=(-0.07--0.47)/ | -0.47 |
=85.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 85.11% mean?
Statera BioPharma (STAB) has a YoY EPS Growth of 85.11% as of Sep. 2022. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Statera BioPharma and its competitors.
Is Statera BioPharma's YoY EPS Growth too high?
Statera BioPharma's current YoY EPS Growth is 85.11%.
How does Statera BioPharma's YoY EPS Growth compare to NRBO and PALI?
Statera BioPharma's YoY EPS Growth of 85.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Statera BioPharma and its competitors. Statera BioPharma's current YoY EPS Growth is 85.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current YoY EPS Growth of 85.11%. The current YoY EPS Growth is 85.11%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Statera BioPharma (STAB), the current YoY EPS Growth is 85.11% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.